Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11117973

    Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms

    Inhibrx, Inc. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11117934

    Oncolytic virus platform to treat cancers with myxoma virus

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11110108

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11110092

    Methods of treating hematologic cancers

    BioCryst Pharmaceuticals, Inc. · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11111238

    Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11110089

    Pyridazinones and their use in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11110181

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11110106

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11111306

    IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11103491

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11104957

    Compositions and methods for treating cancers

    APTOSE BIOSCIENCES INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11098103

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11096996

    Cancer vaccines and vaccination methods

    Precision Lifesciences Group LLC · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11098054

    Englerin derivatives for treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Sciences · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11090332

    Antigen specific mRNA cellular cancer vaccines

    Regen Biopharma, Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11090286

    Methods of treating and preventing breast cancer with S-equol

    The Board of Regents of the University of Texas System · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11091516

    Synthetic binder of breast cancer stem cells

    The Board of Regents of the University of Texas System · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11090396

    Compounds and methods for the detection of TRPV-6 cancers and drug delivery

    Soricimed Biopharma Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11090311

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11091555

    Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy

    Five Prime Therapeutics, Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11084872

    Method for treating breast cancer

    ADC THERAPEUTICS SA · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11083752

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11077078

    Compositions and methods for the treatment of cancer

    KoDiscovery, LLC · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11078295

    Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11078245

    Colon and pancreas cancer peptidomimetics

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11078289

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11078256

    Methods and compositions for inhibiting cancer cell growth

    The Board of Regents of the University of Texas System · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11071727

    Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors

    Northwestern University · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11071781

    Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11071755

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11071778

    Combination product for use in tumor vaccination

    DCPRIME B.V. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11072600

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11066405

    Bicyclic compounds and their use in the treatment of cancer

    TEMPEST THERAPEUTICS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11058664

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11059878

    Therapeutic targeting of SET1B/compass pathway for treating cancers

    Northwestern University · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11058709

    Methods of treating breast cancer

    Ionis Pharmaceuticals, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11058728

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11052089

    Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype

    The Regents of the University of California · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11052144

    Methods of tumor vaccination

    DCPRIME B.V. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11053310

    Antibodies for the treatment of cancers

    The Regents of the University of California · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11052115

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11052116

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11052057

    Use of cysteamine and derivatives thereof to suppress tumor metastases

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11053314

    Methods to eliminate cancer stem cells by targeting CD47

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11045482

    Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

    Corcept Therapeutics Incorporated · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11045472

    Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11045504

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. SG 11202104918P

    THERAPY FOR TREATING CANCER WITH AN INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA ENCODING 4-1BBL (CD137L) AND/OR CD40L

    BAVARIAN NORDIC AS [DK] · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.